MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

14.44 4.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.19

Максимум

Ключови измерители
By Trading Economics
Приходи	31M -11M
Продажби	27M 71M
EPS	-0.09
Марж на печалбата	-15.118
Служители	342
EBITDA	29M -4.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+37.38% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	155M 1.6B
Предишно отваряне	10.03
Предишно затваряне	14.44

Настроения в новините

By Acuity

51%

49%

318 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

14.01 / 14.57 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.04.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

22.04.2025 г., 20:55 ч. UTC

Печалби

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

22.04.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise After Wall Street Rally -- Market Talk

22.04.2025 г., 23:49 ч. UTC

Пазарно говорене

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

22.04.2025 г., 23:47 ч. UTC

Топ новини

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

22.04.2025 г., 23:08 ч. UTC

Придобивния, сливания и поглъщания

Woodside: No Change to Annual Guidance

22.04.2025 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

22.04.2025 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

22.04.2025 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

22.04.2025 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

22.04.2025 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Scarborough Energy Project 82% Complete

22.04.2025 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

22.04.2025 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Beaumont New Ammonia Project 90% Complete

22.04.2025 г., 23:04 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

22.04.2025 г., 23:04 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

22.04.2025 г., 23:04 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

22.04.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

22.04.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

22.04.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy 1Q Revenue US$3.315 Billion

22.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

22.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

22.04.2025 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

22.04.2025 г., 22:31 ч. UTC

Печалби

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

22.04.2025 г., 22:26 ч. UTC

Топ новини

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

22.04.2025 г., 22:16 ч. UTC

Топ новини

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

22.04.2025 г., 22:16 ч. UTC

Пазарно говорене

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

22.04.2025 г., 22:04 ч. UTC

Топ новини

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

22.04.2025 г., 21:42 ч. UTC

Печалби

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

22.04.2025 г., 21:21 ч. UTC

Топ новини

Печалби

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

22.04.2025 г., 21:19 ч. UTC

Топ новини

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

37.38% нагоре

12-месечна прогноза

Среден 19 USD 37.38%

Висок 21 USD

Нисък 15 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

14.01 / 14.57Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

318 / 382 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.